GMAB
Price
$20.30
Change
-$0.14 (-0.68%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
12.77B
35 days until earnings call
INCY
Price
$68.45
Change
+$0.28 (+0.41%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
13.2B
33 days until earnings call
Interact to see
Advertisement

GMAB vs INCY

Header iconGMAB vs INCY Comparison
Open Charts GMAB vs INCYBanner chart's image
Genmab A/S ADS
Price$20.30
Change-$0.14 (-0.68%)
Volume$27.68K
Capitalization12.77B
Incyte
Price$68.45
Change+$0.28 (+0.41%)
Volume$261.02K
Capitalization13.2B
GMAB vs INCY Comparison Chart in %
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. INCY commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and INCY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (GMAB: $20.43 vs. INCY: $68.17)
Brand notoriety: GMAB: Not notable vs. INCY: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 87% vs. INCY: 118%
Market capitalization -- GMAB: $12.77B vs. INCY: $13.2B
GMAB [@Biotechnology] is valued at $12.77B. INCY’s [@Biotechnology] market capitalization is $13.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • INCY’s FA Score: 1 green, 4 red.
According to our system of comparison, INCY is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 3 TA indicator(s) are bullish while INCY’s TA Score has 3 bullish TA indicator(s).

  • GMAB’s TA Score: 3 bullish, 7 bearish.
  • INCY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, INCY is a better buy in the short-term than GMAB.

Price Growth

GMAB (@Biotechnology) experienced а -0.44% price change this week, while INCY (@Biotechnology) price change was +0.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

GMAB is expected to report earnings on Aug 07, 2025.

INCY is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($13.2B) and GMAB($12.8B) have the same market capitalization . INCY has higher P/E ratio than GMAB: INCY (340.85) vs GMAB (11.99). INCY YTD gains are higher at: -1.303 vs. GMAB (-2.108). GMAB has higher annual earnings (EBITDA): 1.35B vs. INCY (407M). GMAB has more cash in the bank: 3.23B vs. INCY (2.41B). INCY has less debt than GMAB: INCY (43.1M) vs GMAB (143M). INCY has higher revenues than GMAB: INCY (4.41B) vs GMAB (3.12B).
GMABINCYGMAB / INCY
Capitalization12.8B13.2B97%
EBITDA1.35B407M332%
Gain YTD-2.108-1.303162%
P/E Ratio11.99340.854%
Revenue3.12B4.41B71%
Total Cash3.23B2.41B134%
Total Debt143M43.1M332%
FUNDAMENTALS RATINGS
GMAB vs INCY: Fundamental Ratings
GMAB
INCY
OUTLOOK RATING
1..100
7072
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4289
PRICE GROWTH RATING
1..100
5850
P/E GROWTH RATING
1..100
931
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GMAB's Valuation (58) in the null industry is somewhat better than the same rating for INCY (93) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than INCY’s over the last 12 months.

GMAB's Profit vs Risk Rating (100) in the null industry is in the same range as INCY (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to INCY’s over the last 12 months.

GMAB's SMR Rating (42) in the null industry is somewhat better than the same rating for INCY (89) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than INCY’s over the last 12 months.

INCY's Price Growth Rating (50) in the Biotechnology industry is in the same range as GMAB (58) in the null industry. This means that INCY’s stock grew similarly to GMAB’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for GMAB (93) in the null industry. This means that INCY’s stock grew significantly faster than GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABINCY
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
56%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
59%
Advances
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 24 days ago
60%
Declines
ODDS (%)
Bearish Trend 11 days ago
68%
Bearish Trend 4 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EMDV45.930.15
+0.33%
ProShares MSCI Emerg Mkts Div Growers
INKM32.460.04
+0.12%
SPDR® SSgA Income Allocation ETF
BTZ10.98-0.01
-0.09%
BlackRock Credit Allocation Income Trust
NUW13.73-0.03
-0.22%
Nuveen AMT-Free Municipal Value Fund
MHNC16.75-0.04
-0.24%
MAIDEN HOLDINGS NORTH AMERICA Ltd

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.49%
GNMSF - GMAB
58%
Loosely correlated
N/A
AXON - GMAB
47%
Loosely correlated
-0.09%
ARGX - GMAB
40%
Loosely correlated
+0.42%
ARVN - GMAB
38%
Loosely correlated
+3.54%
TECH - GMAB
37%
Loosely correlated
+2.11%
More

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with TECH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-0.81%
TECH - INCY
41%
Loosely correlated
+2.11%
REGN - INCY
39%
Loosely correlated
+4.33%
AXON - INCY
39%
Loosely correlated
-0.09%
LGND - INCY
37%
Loosely correlated
+0.61%
SYRE - INCY
36%
Loosely correlated
N/A
More